Trials | No. of patients | T+L/L | T | RR or HR (95% CI) | P-value | I2 (%) |
---|---|---|---|---|---|---|
OS (T+L vs. T) | ||||||
 ALTTO | 4190 | 2093 | 2097 | 0.83 [0.69, 1.01] | 0.06 | 15% |
 ALTTOa | 4188 | 2091 | 2097 | 0.82 [0.68, 0.99] | 0.04 | 12% |
 CALGB 40601 | 238 | 118 | 120 | 0.86 [0.75, 0.99] | 0.04 | 0% |
 CHER-Lob | 82 | 46 | 36 | 0.84 [0.73, 0.97] | 0.02 | 15% |
 NeoALTTO | 301 | 152 | 149 | 0.85 [0.74, 0.99] | 0.03 | 9% |
 Pooled estimate | 8999 | 4500 | 4499 | 0.84 [0.73, 0.97] | 0.02 | 0% |
OS (L vs. T) | ||||||
 ALTTO | 4197 | 2100 | 2097 | 1.18 [0.97, 1.45] | 0.19 | 35% |
 CALGB 40601 | 187 | 67 | 120 | 1.26 [1.08, 1.47] | 0.003 | 43% |
 CEREBEL | 540 | 271 | 269 | 1.24 [1.05, 1.47] | 0.01 | 42% |
 GeparQuinto | 615 | 308 | 307 | 1.32 [1.13, 1.54] | 0.0006 | 0% |
 NCIC CTG MA.31 | 537 | 270 | 267 | 1.22 [1.03, 1.44] | 0.02 | 35% |
 NeoALTTO | 303 | 154 | 149 | 1.30 [1.11, 1.52] | 0.001 | 16% |
 Pooled estimate | 6379 | 3170 | 3209 | 1.26 [1.08, 1.46] | 0.003 | 29% |
PFS (L vs. T) | ||||||
 CEREBEL | 540 | 271 | 269 | 1.47 [1.03, 2.09] | 0.03 | / |
 NCIC CTG MA.31 | 537 | 270 | 267 | 1.30 [1.04, 1.64] | 0.02 | / |
 Pooled estimate | 1077 | 541 | 536 | 1.35 [1.11, 1.64] | 0.002 | 0% |
DFS/EFS (T+L vs. T) | ||||||
 ALTTO | 4190 | 2093 | 2097 | 0.91 [0.79, 1.04] | 0.15 | 35% |
 ALTTOa | 4188 | 2091 | 2097 | 0.84 [0.73, 0.97] | 0.01 | 10% |
 CHER-Lob | 82 | 46 | 36 | 0.89 [0.81, 0.99] | 0.03 | 0% |
 NeoALTTO | 301 | 152 | 149 | 0.89 [0.80, 0.99] | 0.03 | 36% |
 Pooled estimate | 8761 | 4382 | 4379 | 0.89 [0.80, 0.98] | 0.02 | 9% |
DFS/EFS (L vs. T) (REM) | ||||||
 ALTTO | 4197 | 2100 | 2097 | 0.98 [0.75, 1.27] | 0.88 | 0% |
 CHER-Lob | 75 | 39 | 36 | 1.20 [0.98, 1.46] | 0.08 | 28% |
 GeparQuinto | 615 | 308 | 307 | 1.12 [0.81, 1.55] | 0.49 | 48% |
 NeoALTTO | 303 | 154 | 149 | 1.15 [0.87, 1.53] | 0.31 | 45% |
 Pooled estimate | 5190 | 2601 | 2589 | 1.13 [0.91, 1.42] | 0.27 | 36% |
pCR (T+L vs. T, ypT0/is ypN0) | ||||||
 CALGB 40601 | 233 | 116 | 117 | 1.29 [1.13, 1.48] | 0.0002 | 27% |
 CHER-Lob | 79 | 43 | 36 | 1.25 [1.11, 1.41] | 0.0003 | 14% |
 EORTC 10054 | 100 | 48 | 52 | 1.29 [1.14, 1.47] | < 0.0001 | 21% |
 LPT109096 | 66 | 33 | 33 | 1.29 [1.14, 1.46] | < 0.0001 | 16% |
 NeoALTTO | 290 | 145 | 145 | 1.19 [1.05, 1.35] | 0.008 | 0% |
 NSABP B-41 | 347 | 171 | 176 | 1.30 [1.12, 1.51] | 0.0007 | 28% |
 TRIO-US B07 | 92 | 58 | 34 | 1.29 [1.14, 1.46] | < 0.0001 | 25% |
 Pooled estimate | 1207 | 614 | 593 | 1.27 [1.13, 1.43] | < 0.0001 | 14% |
pCR (L vs. T, ypT0/is ypN0) | ||||||
 CALGB 40601 | 179 | 62 | 117 | 0.74 [0.65, 0.84] | <0.00001 | 28% |
 CHER-Lob | 71 | 35 | 36 | 0.73 [0.64, 0.82] | <0.00001 | 28% |
 EORTC 10054 | 74 | 22 | 52 | 0.73 [0.65, 0.83] | <0.00001 | 32% |
 GEICAM/2006-14 | 99 | 51 | 48 | 0.75 [0.66, 0.85] | <0.00001 | 14% |
 GeparQuinto | 615 | 308 | 307 | 0.76 [0.66, 0.89] | 0.0005 | 23% |
 LPT109096 | 67 | 34 | 33 | 0.73 [0.65, 0.83] | <0.00001 | 32% |
 NeoALTTO | 295 | 150 | 145 | 0.73 [0.65, 0.83] | <0.00001 | 32% |
 NSABP B-41 | 347 | 171 | 176 | 0.67 [0.58, 0.77] | <0.00001 | 0% |
 TRIO-US B07 | 70 | 36 | 34 | 0.74 [0.66, 0.84] | <0.00001 | 24% |
 Pooled estimate | 1817 | 869 | 948 | 0.73 [0.65, 0.83] | <0.00001 | 22% |
pCR (T+L vs. T, ypT0/is ypN0/+) | ||||||
 CALGB 40601 | 238 | 118 | 120 | 1.33 [1.15, 1.54] | <0.0001 | 63% |
 EORTC 10054 | 100 | 48 | 52 | 1.33 [1.17, 1.52] | <0.0001 | 61% |
 NeoALTTO | 301 | 152 | 149 | 1.20 [1.05, 1.38] | 0.008 | 0% |
 NSABP B-41 | 348 | 171 | 177 | 1.41 [1.19, 1.67] | <0.0001 | 49% |
 Pooled estimate | 987 | 489 | 498 | 1.31 [1.16, 1.49] | <0.0001 | 45% |
pCR (L vs. T, ypT0/is ypN0/+) | ||||||
 CALGB 40601 | 187 | 67 | 120 | 0.80 [0.71, 0.91] | 0.0005 | 60% |
 EORTC 10054 | 74 | 22 | 52 | 0.79 [0.70, 0.89] | <0.0001 | 63% |
 GEICAM/2006-14 | 99 | 51 | 48 | 0.81 [0.72, 0.92] | 0.0007 | 47% |
 GeparQuinto | 615 | 308 | 307 | 0.84 [0.72, 0.98] | 0.02 | 53% |
 NeoALTTO | 303 | 154 | 149 | 0.78 [0.69, 0.89] | 0.0001 | 64% |
 NSABP B-41 | 348 | 171 | 177 | 0.72 [0.62, 0.83] | <0.00001 | 0% |
 Pooled estimate | 1626 | 773 | 853 | 0.79 [0.70, 0.89] | <0.0001 | 54% |
RFS (T+L vs. T) (REM) | ||||||
 ALTTO | 4190 | 2093 | 2097 | 0.32 [0.14, 0.71] | 0.005 | / |
 CALGB 40601 | 238 | 118 | 120 | 0.86 [0.74, 1.00] | 0.05 | / |
 Pooled estimate | 4428 | 2211 | 2217 | 0.57 [0.22, 1.48] | 0.25 | 82% |
ORR (T+L vs. T) | ||||||
 EORTC 10054 | 99 | 47 | 52 | 1.04 [0.98, 1.12] | 0.21 | 58% |
 LPT109096 | 66 | 33 | 33 | 1.02 [0.96, 1.09] | 0.50 | 71% |
 NeoALTTO | 301 | 152 | 149 | 0.96 [0.90, 1.03] | 0.28 | 0% |
 NSABP B-41 | 331 | 164 | 167 | 1.05 [0.95, 1.17] | 0.34 | 65% |
 Pooled estimate | 797 | 396 | 401 | 1.02 [0.96, 1.09] | 0.53 | 56% |
ORR (L vs. T) | ||||||
 CEREBEL | 540 | 271 | 269 | 1.00 [0.95, 1.04] | 0.88 | 0% |
 EORTC 10054 | 73 | 21 | 52 | 0.98 [0.93, 1.03] | 0.48 | 0% |
 GEICAM/2006-14 | 99 | 51 | 48 | 0.98 [0.93, 1.03] | 0.43 | 0% |
 GeparQuinto | 615 | 308 | 307 | 0.98 [0.91, 1.06] | 0.66 | 0% |
 LPT109096 | 67 | 34 | 33 | 0.97 [0.93, 1.03] | 0.32 | 0% |
 NeoALTTO | 303 | 154 | 149 | 0.97 [0.91, 1.02] | 0.20 | 0% |
 NSABP B-41 | 330 | 163 | 167 | 0.97 [0.91, 1.03] | 0.34 | 0% |
 Pooled estimate | 2027 | 1002 | 1025 | 0.98 [0.93, 1.03] | 0.41 | 0% |
DCR (L vs. T) | ||||||
 CEREBEL | 540 | 271 | 269 | 0.96 [0.93, 1.00] | 0.03 | 24% |
 EORTC 10054 | 73 | 21 | 52 | 0.96 [0.91, 1.02] | 0.21 | 0% |
 GeparQuinto | 615 | 308 | 307 | 0.93 [0.79, 1.09] | 0.36 | 0% |
 Pooled estimate | 1228 | 600 | 628 | 0.96 [0.90, 1.01] | 0.13 | 0% |
Rate of BCS (T+L vs. T) | ||||||
 CHER-Lob | 81 | 45 | 36 | 1.00 [0.86, 1.16] | 0.99 | 0% |
 EORTC 10054 | 102 | 50 | 52 | 0.99 [0.86, 1.14] | 0.88 | 0% |
 NeoALTTO | 286 | 143 | 143 | 0.97 [0.83, 1.14] | 0.73 | 0% |
 NSABP B-41 | 348 | 171 | 177 | 1.08 [0.90, 1.30] | 0.40 | 0% |
 Pooled estimate | 817 | 409 | 408 | 1.01 [0.88, 1.15] | 0.94 | 0% |
Rate of BCS (L vs. T) | ||||||
 CHER-Lob | 74 | 38 | 36 | 0.95 [0.86, 1.05] | 0.31 | 28% |
 EORTC 10054 | 74 | 22 | 52 | 0.93 [0.84, 1.03] | 0.16 | 0% |
 GEICAM/2006-14 | 99 | 51 | 48 | 0.94 [0.85, 1.04] | 0.22 | 29% |
 GeparQuinto | 615 | 308 | 307 | 0.97 [0.85, 1.11] | 0.64 | 27% |
 NeoALTTO | 286 | 143 | 143 | 0.91 [0.82, 1.01] | 0.08 | 0% |
 NSABP B-41 | 348 | 171 | 177 | 0.98 [0.88, 1.09] | 0.70 | 4% |
 Pooled estimate | 1496 | 733 | 763 | 0.94 [0.86, 1.04] | 0.24 | 14% |
CHF (T+L vs. T) | ||||||
 TRIO-US B07 | 92 | 58 | 34 | 0.95 [0.73, 1.23] | 0.71 | 65% |
 NSABP B-41 | 351 | 173 | 178 | 1.00 [0.77, 1.31] | 0.98 | 62% |
 NeoALTTO | 301 | 152 | 149 | 0.94 [0.73, 1.22] | 0.66 | 75% |
 EORTC 10054 | 103 | 50 | 53 | 0.95 [0.73, 1.23] | 0.71 | 65% |
 CHER-Lob | 82 | 46 | 36 | 0.95 [0.73, 1.23] | 0.71 | 65% |
 CALGB 40601 | 235 | 117 | 118 | 0.95 [0.73, 1.23] | 0.71 | 65% |
 ALTTOa | 4152 | 2076 | 2076 | 1.17 [0.84, 1.65] | 0.35 | 55% |
 ALTTO | 4137 | 2061 | 2076 | 0.65 [0.44, 0.97] | 0.04 | 31% |
 Pooled estimate | 9453 | 4733 | 4720 | 0.95 [0.73, 1.23] | 0.71 | 65% |
CHF (L vs. T) | ||||||
 WJOG6110B/ELTOP | 86 | 43 | 43 | 0.88 [0.61, 1.26] | 0.47 | 55% |
 TRIO-US B07 | 70 | 36 | 34 | 0.89 [0.62, 1.28] | 0.54 | 45% |
 NSABP B-41 | 351 | 173 | 178 | 0.88 [0.60, 1.28] | 0.50 | 58% |
 NeoALTTO | 303 | 154 | 149 | 0.89 [0.62, 1.28] | 0.54 | 45% |
 GeparQuinto | 615 | 308 | 307 | 0.79 [0.55, 1.15] | 0.22 | 2% |
 EORTC 10054 | 75 | 22 | 53 | 0.86 [0.60, 1.24] | 0.43 | 45% |
 CHER-Lob | 78 | 39 | 39 | 0.89 [0.62, 1.28] | 0.54 | 45% |
 CALGB 40601 | 182 | 64 | 118 | 0.89 [0.62, 1.28] | 0.54 | 45% |
 ALTTO | 4133 | 2057 | 2076 | 2.03 [0.92, 4.48] | 0.08 | 18% |
 Pooled estimate | 5893 | 2896 | 2997 | 0.89 [0.62, 1.28] | 0.54 | 45% |
Decline of LVEF (T+L vs. T) | ||||||
 TRIO-US B07 | 92 | 58 | 34 | 0.82 [0.67, 1.01] | 0.06 | 64% |
 NSABP B-41 | 351 | 173 | 178 | 0.82 [0.67, 1.01] | 0.08 | 52% |
 NeoALTTO | 301 | 152 | 149 | 0.82 [0.67, 1.01] | 0.06 | 64% |
 EORTC 10054 | 103 | 50 | 53 | 0.82 [0.67, 1.01] | 0.06 | 52% |
 CHER-Lob | 82 | 46 | 36 | 0.83 [0.67, 1.01] | 0.07 | 62% |
 CALGB 40601 | 235 | 117 | 118 | 0.82 [0.67, 1.01] | 0.06 | 52% |
 ALTTOa | 4152 | 2076 | 2076 | 1.05 [0.80, 1.37] | 0.72 | 0% |
 ALTTO | 4137 | 2061 | 2076 | 0.59 [0.43, 0.80] | 0.0009 | 0% |
 Pooled estimate | 9453 | 4733 | 4720 | 0.82 [0.67, 1.01] | 0.06 | 52% |
Decline of LVEF (L vs. T) | ||||||
 WJOG6110B/ELTOP | 86 | 43 | 43 | 0.67 [0.50, 0.90] | 0.008 | 0% |
 TRIO-US B07 | 70 | 36 | 34 | 0.66 [0.49, 0.89] | 0.006 | 0% |
 NSABP B-41 | 351 | 173 | 178 | 0.67 [0.50, 0.90] | 0.008 | 0% |
 NeoALTTO | 303 | 154 | 149 | 0.67 [0.49, 0.90] | 0.008 | 0% |
 GeparQuinto | 615 | 308 | 307 | 0.68 [0.51, 0.93] | 0.01 | 0% |
 EORTC 10054 | 75 | 22 | 53 | 0.65 [0.48, 0.88] | 0.005 | 0% |
 CHER-Lob | 75 | 39 | 36 | 0.67 [0.50, 0.91] | 0.010 | 0% |
 CALGB 40601 | 182 | 64 | 118 | 0.67 [0.50, 0.90] | 0.008 | 0% |
 ALTTO | 4133 | 2057 | 2076 | 0.82 [0.30, 2.24] | 0.70 | 0% |
 Pooled estimate | 5890 | 2896 | 2994 | 0.67 [0.50, 0.90] | 0.008 | 0% |
Diarrhea (T+L vs. T) | ||||||
 ALTTO | 4137 | 2061 | 2076 | 6.06 [4.37, 8.41] | <0.00001 | 28% |
 ALTTOa | 4152 | 2076 | 2076 | 11.39 [8.30, 15.63] | <0.00001 | 0% |
 CALGB 40601 | 235 | 117 | 118 | 8.19 [6.36, 10.55] | <0.00001 | 61% |
 CHER-Lob | 82 | 46 | 36 | 8.25 [6.42, 10.61] | <0.00001 | 61% |
 EORTC 10054 | 103 | 50 | 53 | 8.31 [6.46, 10.67] | <0.00001 | 62% |
 LPT109096 | 63 | 31 | 32 | 8.35 [6.50, 10.72] | <0.00001 | 62% |
 NeoALTTO | 297 | 149 | 148 | 8.25 [6.38, 10.67] | <0.00001 | 62% |
 NSABP B-41 | 351 | 173 | 178 | 8.11 [6.27, 10.49] | <0.00001 | 60% |
 TRIO-US B07 | 92 | 58 | 34 | 8.30 [6.46, 10.67] | <0.00001 | 62% |
 Pooled estimate | 9512 | 4761 | 4751 | 8.32 [6.49, 10.68] | <0.00001 | 57% |
Diarrhea (L vs. T) | ||||||
 ALTTO | 4133 | 2057 | 2076 | 3.81 [2.78, 5.21] | <0.00001 | 76% |
 CALGB 40601 | 182 | 64 | 118 | 5.48 [4.28, 7.02] | <0.00001 | 82% |
 CEREBEL | 536 | 269 | 267 | 7.62 [5.73, 10.11] | <0.00001 | 11% |
 CHER-Lob | 75 | 39 | 36 | 5.52 [4.32, 7.05] | <0.00001 | 82% |
 EORTC 10054 | 75 | 22 | 53 | 5.63 [4.41, 7.19] | <0.00001 | 83% |
 GeparQuinto | 615 | 308 | 307 | 5.76 [4.45, 7.46] | <0.00001 | 83% |
 LPT109096 | 66 | 34 | 32 | 5.63 [4.41, 7.19] | <0.00001 | 83% |
 NeoALTTO | 299 | 151 | 148 | 5.40 [4.20, 6.95] | <0.00001 | 82% |
 NSABP B-41 | 351 | 173 | 178 | 5.43 [4.22, 6.98] | <0.00001 | 82% |
 TRIO-US B07 | 70 | 36 | 34 | 5.64 [4.41, 7.20] | <0.00001 | 83% |
 WJOG6110B/ELTOP | 86 | 43 | 43 | 5.85 [4.55, 7.51] | <0.00001 | 81% |
 Pooled estimate | 6488 | 3196 | 3292 | 5.62 [4.41, 7.17] | <0.00001 | 81% |
Neutropenia (T+L vs. T) | ||||||
 EORTC 10054 | 103 | 50 | 53 | 1.19 [0.81, 1.74] | 0.39 | 22% |
 LPT109096 | 63 | 31 | 32 | 1.20 [0.89, 1.62] | 0.23 | 0% |
 NeoALTTO | 297 | 149 | 148 | 1.04 [0.76, 1.41] | 0.82 | 0% |
 NSABP B-41 | 351 | 173 | 178 | 1.27 [0.87, 1.85] | 0.22 | 18% |
 TRIO-US B07 | 92 | 58 | 34 | 1.16 [0.85, 1.57] | 0.35 | 23% |
 Pooled estimate | 906 | 461 | 445 | 1.16 [0.86, 1.56] | 0.33 | 0% |
Neutropenia (L vs. T) | ||||||
 CEREBEL | 536 | 269 | 267 | 1.01 [0.91, 1.11] | 0.86 | 64% |
 EORTC 10054 | 75 | 22 | 53 | 0.98 [0.89, 1.09] | 0.76 | 65% |
 GeparQuinto | 615 | 308 | 307 | 1.17 [0.88, 1.56] | 0.28 | 61% |
 LPT109096 | 66 | 34 | 32 | 1.00 [0.90, 1.10] | 0.98 | 62% |
 NeoALTTO | 299 | 151 | 148 | 0.92 [0.83, 1.02] | 0.10 | 0% |
 NSABP B-41 | 351 | 173 | 178 | 0.99 [0.89, 1.09] | 0.82 | 65% |
 TRIO-US B07 | 70 | 36 | 34 | 0.99 [0.89, 1.09] | 0.78 | 65% |
 WJOG6110B/ELTOP | 86 | 43 | 43 | 0.99 [0.90, 1.10] | 0.87 | 65% |
 Pooled estimate | 2098 | 1036 | 1062 | 0.99 [0.89, 1.09] | 0.82 | 59% |
Fatigue (T+L vs. T) | ||||||
 CHER-Lob | 82 | 46 | 36 | 0.73 [0.34, 1.57] | 0.42 | 0% |
 EORTC 10054 | 103 | 50 | 53 | 0.95 [0.46, 1.94] | 0.88 | 0% |
 NSABP B-41 | 351 | 173 | 178 | 0.87 [0.30, 2.48] | 0.79 | 0% |
 TRIO-US B07 | 92 | 58 | 34 | 0.84 [0.40, 1.76] | 0.64 | 0% |
 Pooled estimate | 628 | 327 | 301 | 0.84 [0.42, 1.67] | 0.62 | 0% |
Fatigue (L vs. T) | ||||||
 CEREBEL | 536 | 269 | 267 | 1.43 [0.95, 2.15] | 0.09 | 0% |
 CHER-Lob | 75 | 39 | 36 | 1.44 [0.97, 2.14] | 0.07 | 0% |
 EORTC 10054 | 75 | 22 | 53 | 1.41 [0.95, 2.09] | 0.09 | 0% |
 GeparQuinto | 615 | 308 | 307 | 1.45 [0.83, 2.54] | 0.20 | 0% |
 NSABP B-41 | 351 | 173 | 178 | 1.47 [0.94, 2.29] | 0.09 | 0% |
 TRIO-US B07 | 70 | 36 | 34 | 1.44 [0.97, 2.14] | 0.07 | 0% |
 Pooled estimate | 1722 | 847 | 875 | 1.44 [0.97, 2.11] | 0.07 | 0% |
Rash/Skin toxicity (T+L vs. T) | ||||||
 ALTTO | 4137 | 2061 | 2076 | 5.75 [3.57, 9.24] | <0.00001 | 0% |
 ALTTOa | 4152 | 2076 | 2076 | 6.80 [4.25, 10.87] | <0.00001 | 11% |
 CALGB 40601 | 235 | 117 | 118 | 6.66 [4.54, 9.77] | <0.00001 | 9% |
 CHER-Lob | 82 | 46 | 36 | 7.11 [4.85, 10.44] | <0.00001 | 0% |
 EORTC 10054 | 103 | 50 | 53 | 7.08 [4.84, 10.38] | <0.00001 | 0% |
 NeoALTTO | 297 | 149 | 148 | 6.74 [4.63, 9.82] | <0.00001 | 11% |
 NSABP B-41 | 351 | 173 | 178 | 6.77 [4.66, 9.84] | <0.00001 | 10% |
 Pooled estimate | 9357 | 4672 | 4685 | 6.75 [4.66, 9.77] | <0.00001 | 0% |
Rash/Skin toxicity (L vs. T) | ||||||
 ALTTO | 4133 | 2057 | 2076 | 6.45 [3.38, 12.29] | <0.00001 | 0% |
 CALGB 40601 | 182 | 64 | 118 | 8.67 [5.51, 13.65] | <0.00001 | 0% |
 CEREBEL | 536 | 269 | 267 | 8.93 [5.73, 13.93] | <0.00001 | 0% |
 CHER-Lob | 75 | 39 | 36 | 9.33 [5.91, 14.72] | <0.00001 | 0% |
 EORTC 10054 | 75 | 22 | 53 | 9.31 [5.94, 14.58] | <0.00001 | 0% |
 GeparQuinto | 615 | 308 | 307 | 8.48 [5.37, 13.38] | <0.00001 | 0% |
 NeoALTTO | 299 | 151 | 148 | 8.75 [5.61, 13.65] | <0.00001 | 0% |
 NSABP B-41 | 351 | 173 | 178 | 8.55 [5.51, 13.28] | <0.00001 | 0% |
 WJOG6110B/ELTOP | 86 | 43 | 43 | 8.75 [5.63, 13.58] | <0.00001 | 0% |
 Pooled estimate | 6352 | 3126 | 3226 | 8.71 [5.64, 13.45] | <0.00001 | 0% |
Vomiting (T+L vs. T) | ||||||
 CHER-Lob | 82 | 46 | 36 | 2.27 [0.80, 6.44] | 0.12 | 0% |
 EORTC 10054 | 103 | 50 | 53 | 2.10 [0.85, 5.19] | 0.11 | 0% |
 LPT109096 | 63 | 31 | 32 | 2.11 [0.85, 5.21] | 0.11 | 0% |
 NSABP B-41 | 351 | 173 | 178 | 2.31 [0.64, 8.37] | 0.20 | 0% |
 Pooled estimate | 599 | 300 | 299 | 2.17 [0.91, 5.19] | 0.08 | 0% |
Vomiting (L vs. T) | ||||||
 CEREBEL | 536 | 269 | 267 | 1.39 [0.68, 2.84] | 0.37 | 0% |
 CHER-Lob | 75 | 39 | 36 | 1.28 [0.65, 2.53] | 0.48 | 0% |
 EORTC 10054 | 75 | 22 | 53 | 1.29 [0.69, 2.43] | 0.42 | 0% |
 GeparQuinto | 615 | 308 | 307 | 1.56 [0.73, 3.33] | 0.25 | 0% |
 LPT109096 | 66 | 34 | 32 | 1.24 [0.65, 2.38] | 0.51 | 0% |
 NSABP B-41 | 351 | 173 | 178 | 1.05 [0.49, 2.26] | 0.89 | 0% |
 Pooled estimate | 1718 | 845 | 873 | 1.29 [0.69, 2.43] | 0.42 | 0% |
Nausea (T+L vs. T) | ||||||
 CHER-Lob | 82 | 46 | 36 | 1.45 [0.46, 4.55] | 0.52 | 12% |
 EORTC 10054 | 103 | 50 | 53 | 2.33 [0.80, 6.76] | 0.12 | 0% |
 LPT109096 | 63 | 31 | 32 | 1.50 [0.57, 3.96] | 0.41 | 7% |
 NSABP B-41 | 351 | 173 | 178 | 1.24 [0.40, 3.91] | 0.71 | 0% |
 Pooled estimate | 599 | 300 | 299 | 1.61 [0.64, 4.06] | 0.31 | 0% |
Nausea (L vs. T) | ||||||
 CEREBEL | 536 | 269 | 267 | 1.03 [0.56, 1.89] | 0.94 | 0% |
 CHER-Lob | 75 | 39 | 36 | 0.98 [0.54, 1.80] | 0.96 | 0% |
 EORTC 10054 | 75 | 22 | 53 | 0.94 [0.52, 1.72] | 0.85 | 0% |
 GeparQuinto | 615 | 308 | 307 | 1.43 [0.60, 3.37] | 0.42 | 0% |
 LPT109096 | 66 | 34 | 32 | 1.02 [0.58, 1.80] | 0.94 | 0% |
 NSABP B-41 | 351 | 173 | 178 | 0.97 [0.53, 1.77] | 0.92 | 0% |
 Pooled estimate | 1718 | 845 | 873 | 1.02 [0.58, 1.80] | 0.94 | 0% |